Efficacy, Safety, and Acceptability of Misoprostol in the Treatment of Incomplete Miscarriage: A Systematic Review and Meta-analysis / Eficácia, segurança e aceitabilidade do misoprostol no tratamento do aborto incompleto: Uma revisão sistemática e metanálise

Abstract Objective To assess the efficacy, safety, and acceptability of misoprostol in the treatment of incomplete miscarriage. Data sources The PubMed, Scopus, Embase, Web of Science, Cochrane Library, and Clinical Trials databases (clinicaltrials.gov) were searched for the relevant articles, and search strategies were developed using a combination of thematic Medical Subject Headings terms and text words. The last search was conducted on July 4, 2022. No language restrictions were applied. Selection of studies Randomized clinical trials with patients of gestational age up to 6/7 weeks with a diagnosis of incomplete abortion and who were managed with at least 1 of the 3 types of treatment studied were included. A total of 8,087 studies were screened. Data collection Data were synthesized using the statistical package Review Manager V.5.1 (The Cochrane Collaboration, Oxford, United Kingdom). For dichotomous outcomes, the odds ratio (OR) and 95% confidence interval (CI) were derived for each study. Heterogeneity between the trial results was evaluated using the standard test, I2 statistic. Data synthesis When comparing misoprostol with medical vacuum aspiration (MVA), the rate of complete abortion was higher in the MVA group (OR = 0.16; 95%CI = 0.07-0.36). Hemorrhage or heavy bleeding was more common in the misoprostol group (OR = 3.00; 95%CI = 1.96-4.59), but pain after treatment was more common in patients treated with MVA (OR = 0.65; 95%CI = 0.52-0.80). No statistically significant differences were observed in the general acceptability of the treatments. Conclusion Misoprostol has been determined as a safe option with good acceptance by patients.

Resumo Objetivo Avaliar a eficácia, segurança e aceitabilidade do misoprostol no tratamento do aborto incompleto. Fontes de dados Os bancos de dados PubMed, Scopus, Embase, Web of Science, Cochrane Library e bancos de dados de Ensaios Clínicos (clinicaltrials.gov) foram pesquisados para os artigos relevantes, e estratégias de busca foram desenvolvidas usando uma combinação de termos temáticos de Medical Subject Headings e palavras de texto. A última pesquisa foi realizada em 4 de julho de 2022. Nenhuma restrição de idioma foi aplicada. Seleção dos estudos Foram incluídos ensaios clínicos randomizados com pacientes com idade gestacional até 6/7 semanas com diagnóstico de aborto incompleto e que foram manejadas com pelo menos um dos três tipos de tratamento estudados. Um total de 8.087 estudos foram selecionados. Coleta de dados Os dados foram sintetizados usando o pacote estatístico Review Manager V.5.1 (The Cochrane Collaboration, Oxford, United Kingdom). Para resultados dicotômicos, o odds ratio (OR, na sigla em inglês) e o intervalo de confiança (IC) de 95% foram derivados para cada estudo. A heterogeneidade entre os resultados do ensaio foi avaliada usando o teste padrão, estatística I2. Síntese dos dados Ao comparar misoprostol com aspiração a vácuo médico (MVA, na sigla em inglês), a taxa de aborto completo foi maior no grupo MVA (OR = 0,16; IC95% = 0,07-0,36). Hemorragia ou sangramento intenso foi mais comum no grupo do misoprostol (OR = 3,00; 95%CI = 1,96-4,59), mas a dor após o tratamento foi mais comum em pacientes tratados com MVA (OR = 0,65; 95%CI = 0,52-0,80). Não foram observadas diferenças estatisticamente significativas na aceitabilidade geral dos tratamentos. Conclusão O misoprostol tem se mostrado uma opção segura e com boa aceitação pelos pacientes.

Misoprostol Administration Before Hysteroscopy Procedures - A Retrospective Analysis / O uso do misoprostol prévio aos procedimentos histeroscópicos - Um estudo retrospectivo

Abstract Objective To evaluate the use of misoprostol prior to hysteroscopy procedures regarding technical ease, the presence of side effects, and the occurrence of complications. Methods This is a retrospective, observational, analytical, case-control study, with the review of medical records of 266 patients followed-up at the Gynecological Videoendoscopy Sector of the Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto of the Universidade de São Paulo (HCFMRP - USP, in the Portuguese acronym) from 2014 to 2019, comparing 133 patients who used the drug before the procedure with 133 patients who did not. Results The occurrence of postmenopausal uterine bleeding was the main indication for hysteroscopy and revealed a statistical difference between groups (p < 0.001), being present in 93.23% of the patients in the study group and in 69.7% of the patients in the control group. Only 2 patients (1.5%) in the study group reported adverse effects. Although no statistical differences were observed regarding the occurrence of complications during the procedure (p = 0.0662), a higher total number of complications was noted in the group that used misoprostol (n = 7; 5.26%) compared with the group that did not use the drug (n = 1; 0.75%), a fact that is clinically relevant. When evaluating the ease of the technique (measured by the complete performance of all steps of the hysteroscopy procedure), it was verified that although there was no difference between groups (p = 0.0586), the control group had more than twice as many incompletely performed procedures (n = 17) when compared with the group that used misoprostol previously (n = 8), which is also clinically relevant. Conclusion The use of misoprostol prior to hysteroscopy in our service indicated that the drug can facilitate the performance of the procedure, but not without side effects and presenting higher complication rates.

Resumo Objetivo Avaliação do misoprostol prévio à histeroscopia quanto à facilidade técnica, efeitos colaterais e a ocorrência de complicações durante o procedimento. Métodos Estudo analítico observacional retrospectivo tipo caso controle com revisão de prontuários de 266 pacientes do Setor de Videoendoscopia Ginecológica do Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto - Universidade de São Paulo (HCFMRP - USP), de 2014 a 2019, sendo comparadas 133 pacientes que utilizaram o medicamento prévio ao procedimento com 133 pacientes que não o utilizaram. Resultados Sangramento uterino após a menopausa foi a principal indicação de histeroscopia, apresentando diferença estatística (p < 0,001), estando presente em 93,23% das pacientes do grupo de estudo e em 69,17% das pacientes do grupo controle. Apenas 2 pacientes (1,5%) do grupo de estudo relataram efeitos adversos. Não foram observadas diferenças quanto à presença de complicações durante o procedimento (p = 0,0662), mas observamos um número total de complicações maior no grupo de estudo (n = 7; 5,26%) do que no grupo controle (n = 1; 0,75%), o que é clinicamente relevante. Não houve diferença entre os grupos quanto à facilidade técnica (p = 0,0586), mas o grupo controle apresentou mais do que o dobro de procedimentos não completamente realizados (n = 17) quando comparado com o grupo de estudo (n = 8), o que é clinicamente relevante. Conclusão O uso de misoprostol prévio à histeroscopia no nosso serviço demonstrou que ele pode facilitar a realização do procedimento, mas não é isento de efeitos colaterais e apresenta maiores taxas de complicações.

Use of misoprostol in the treatment of postpartum hemorrhage: a pharmacoepidemiological approach / Uso do misoprostol no tratamento da hemorragia pós-parto: uma abordagem farmacoepidemiológica

ABSTRACT Objective To characterize the use of the drug misoprostol for treatment of postpartum hemorrhage in pregnant women. Methods A descriptive observational study was carried out with secondary data from pregnant women who used misoprostol to treat postpartum hemorrhage in a reference public maternity, from July 2015 to June 2017. Clinical and sociodemographic profiles of pregnant women, how misoprostol was used and success rate in controling postpartum hemorrhage were characterized. Results A total of 717 prescriptions of misoprostol were identified. Of these, 10% were for treatment of postpartum hemorrhage. The majority of pregnant women were young adults, married, with complete high school education, white, residing in urban areas, multiparous (68.1%) and 25% had previous cesarean sections. The mean gestational age was 39 weeks and 51.4% had a cesarean section. There was prophylactic use of oxytocin in 47.2% of women. Treatment of postpartum hemorrhage was successful in 84.7% of women. Of these, 79.2% also used oxytocin and 54.2% methylergonovine. Only 13.5% of pregnant women had less than five prenatal visits, and the main cause of postpartum hemorrhage was uterine atony. There were 13 complications after hemorrhage, 15.3% required blood transfusion and there was one case of maternal death. Conclusion Misoprostol showed to be effective and safe for treating postpartum hemorrhage.

RESUMO Objetivo Caracterizar o uso do medicamento misoprostol para o tratamento da hemorragia pós-parto em gestantes. Métodos Estudo observacional descritivo realizado por meio de dados secundários de gestantes que fizeram uso do misoprostol para tratamento da hemorragia pós-parto em maternidade pública de referência, no período de julho de 2015 a junho de 2017. Caracterizaram-se os perfis clínico e sociodemográfico das gestantes, o padrão de utilização do misoprostol e sua taxa de sucesso no controle da hemorragia pós-parto. Resultados Foram identificadas 717 prescrições do misoprostol. Destas, 10% foram para tratamento da hemorragia pós-parto. Predominaram gestantes adultas jovens, casadas, com Ensino Médio completo, raça branca, da região urbana, multíparas (68,1%) e 25% apresentavam cesáreas prévias. A idade gestacional média foi 39 semanas e 51,4% das gestantes tiveram parto cesárea. Houve uso profilático de ocitocina em 47,2% das mulheres. O tratamento da hemorragia pós-parto eve sucesso em 84,7% das gestantes que usaram misoprostol. Destas, 79,2% também usaram ocitocina e 54,2% metilergometrina. Apenas 13,5% das gestantes tiveram menos de cinco consultas de pré-natal, e a principal causa da hemorragia pós-parto foi atonia uterina. Foram registrados 13 casos de complicações após a hemorragia, 15,3% necessitaram de hemotransfusão e houve um caso de óbito materno. Conclusão O misoprostol demonstrou ser efetivo e seguro para o tratamento da hemorragia pós-parto.

Guía de práctica clínica para el uso de uterotónicos en la prevención de la hemorragia posparto / Clinical practice guide for the use of uterotonics in postpartum hemorrhage prevention

Objetivo: Proveer recomendaciones para mejorar la calidad del cuidado y desenlaces para mujeres que reciben atención del parto, en relación a la prevención de la hemorragia posparto (HPP) por atonía uterina en El Salvador. Métodos: La presente guía fue desarrollada siguiendo los lineamientos del Manual para la elaboración de guías de la Organización Mundial de la Salud1. De forma general, se creó un grupo para la elaboración con enfoque multidisciplinario compuesto por expertos sobre el tema, epidemiólogos, metodólogos y pacientes. Con base en la evidencia proveniente de la guía para el uso de uterotónicos para la prevención de hemorragia posparto, se desarrolló una adaptación para el contexto del sistema de salud de El Salvador2. Se realizó inclusión de evidencia local y la contextualización de sus recomendaciones. Las recomendaciones fueron graduadas en un panel de expertos conformado por profesionales en estadística, enfermería, materno infantil, médicos generales y especialistas en ginecología y obstetricia, perinatología, anestesiología, medicina familiar, economía de la salud, epidemiología, además se incluyó la participación de pacientes siguiendo el enfoque GRADE. Adicionalmente, la guía fue evaluada por pares temáticos y metodológicos. Todos los participantes del panel y del grupo desarrollador firmaron un formato de conflicto de intereses que analizaron los coordinadores de la guía.

Tecnologias de cuidado para prevenção e controle da hemorragia no terceiro estágio do parto: revisão sistemática / Care technologies to prevent and control hemorrhage in the third stage of labor: a systematic review / Tecnologías de cuidado para prevención y control de la hemorragia en la tercera etapa del parto: revisión sistemática

Objetivo identificar evidências acerca das contribuições das tecnologias de cuidado usadas para prevenção e controle da hemorragia no terceiro estágio do parto. Método revisão sistemática com busca em bases de dados. Dois investigadores selecionaram os textos de forma independente na primeira etapa e, na segunda, em reunião de conciliação. Para avaliação da concordância, aplicou-se o coeficiente Kappa; para avaliação do risco de viés e classificação dos níveis de evidência, adotou-se o Grading of Recommendations, Assessment, Development and Evaluation. Resultados incluíram-se 42 artigos; desses, 34 classificados como tecnologias de produto, sendo a maioria produtos farmacológicos; dois referentes ao uso do saco plástico transparente para a coleta de sangue e contribuição do intervalo de nascimento e dos cuidados pré-natais. Os oito artigos classificados como tecnologias de processo se referiam a manejo ativo do terceiro estágio do parto, tração controlada de cordão, massagem uterina e intervenções educacionais. Conclusão as tecnologias de produto e de processo apresentaram evidência alta e moderada confirmada em 61,90% dos artigos. Os níveis de evidência demonstram contribuições das tecnologias para prevenção e controle da hemorragia. Na prática clínica, o enfermeiro deve oferecer cuidados à mulher fundamentados em evidências científicas e construir protocolos sobre as ações de cuidado da enfermagem.

Objective to identify evidence concerning the contribution of health technologies used to prevent and control hemorrhaging in the third stage of labor. Method systematic review with database searches. First, two researchers independently selected the papers and, at a second point in time, held a reconciliation meeting. The Kappa coefficient was used to assess agreement, while the Grading of Recommendations, Assessment, Development and Evaluation was adopted to assess risk of bias and classify level of evidence. Results in this review, 42 papers were included, 34 of which addressed product technologies, most referred to pharmacological products, while two papers addressed the use of blood transparent plastic bags collector and the contribution of birth spacing and prenatal care. The eight papers addressing process technologies included the active management of the third stage of labor, controlled cord traction, uterine massage, and educational interventions. Conclusion product and process technologies presented high and moderate evidence confirmed in 61.90% of the papers. The levels of evidence confirm the contribution of technologies to prevent and control hemorrhaging. Clinical nurses should provide scientific-based care and develop protocols addressing nursing care actions.

Objetivo identificar las evidencias acerca de las contribuciones de las tecnologías de cuidado usadas para la prevención y el control de la hemorragia en la tercera etapa del parto. Método revisión sistemática con búsqueda en bases de datos. Dos investigadores seleccionaron los textos, de forma independiente, en la primera etapa; y, en la segunda en reunión de conciliación. Para evaluación de la concordancia fue aplicado el coeficiente Kappa; para evaluación del riesgo de sesgo y clasificación de los niveles de evidencia, se adoptó el Grading of Recommendations, Assessment, Development and Evaluation. Resultados fueron incluidos 42 artículos; de estos, 34 fueron clasificados como: tecnologías de producto (siendo la mayoría productos farmacológicos), dos referentes a la contribución del saco plástico transparente recolector de sangre y del intervalo de nacimiento y de los cuidados prenatales. Los ocho artículos clasificados como tecnologías de proceso se referían al manejo activo de la tercera etapa del parto, a la tracción controlada del cordón, al masaje uterino y a intervenciones educacionales. Conclusión las tecnologías de producto y de proceso presentaron evidencia alta y moderada, lo que fue confirmado en 61,90% de los artículos. Los niveles de evidencia demuestran las contribuciones de las tecnologías para la prevención y el control de la hemorragia. En la práctica clínica, el enfermero debe ofrecer cuidados a la mujer fundamentados en evidencias científicas y construir protocolos sobre las acciones de cuidado de la enfermería.

Abordagem terapêutica no processo de esvaziamento uterino / Enfoque terapéutico en el proceso de vaciación uterino / Therapeutic approach in the uterine evacuation process

Objetivos identificar a terapêutica utilizada no processo de esvaziamento uterino e traçar o perfil obstétrico das mulheres assistidas nesse processo. Método pesquisa quantitativa, retrospectiva, de caráter exploratório-descritivo, constituída por 466 prontuários de mulheres internadas para esvaziamento uterino, no período de junho de 2015 a junho de 2016. Resultados a idade variou entre 14 e 43 anos, o principal diagnóstico foi o aborto incompleto, responsável por 44,85% das internações, a terapêutica inicial mais utilizada foi o misoprostol (57,71%) e o tempo de internação até o esvaziamento uterino variou entre 0,20 e 137 horas. Conclusão o perfil obstétrico da mulher que vivencia a perda gestacional não difere do encontrado nacionalmente; a curetagem foi a terapêutica final mais utilizada acrescida de alguns desfechos desfavoráveis, como maior tempo de internação e exposição excessiva a medicação.

Objetivos identificar la terapéutica utilizada en el proceso de vaciamiento uterino y trazar el perfil obstétrico de mujeres asistidas en ese proceso. Método investigación cuantitativa, retrospectiva, de carácter exploratorio-descriptivo, constituida por 466 prontuarios de mujeres internadas para vaciamiento uterino, de junio de 2015 a junio de 2016. Resultados edad entre 14 y 43 años, el principal diagnóstico fue el aborto incompleto, responsable por 44,85% de las internaciones, la terapéutica inicial más utilizada fue el misoprostol (57,71%) y el tiempo de internación hasta el vaciamiento uterino varió entre 0,20 y 137 horas. Conclusión el perfil obstétrico de la mujer que vive la pérdida gestacional no difiere de lo encontrado nacionalmente; el curetaje fue la terapia final más utilizada, sumada de algunos resultados desfavorables, como mayor tiempo de internación y exposición excesiva a la medicación.

Objectives identify the therapeutics used in the uterine evacuation process and outline the obstetric profile of the women attended in this process. Method quantitative, retrospective, exploratory and descriptive research, consisting of 466 records of women hospitalized for uterine evacuation between June 2015 and June 2016. Results ages ranged between 14 and 43 years. The main diagnosis was incomplete abortion, responsible for 44.85% of the hospitalizations. The most used initial therapy was misoprostol (57.71%) and the length of hospitalization before the uterine evacuation ranged between 0.20 and 137 hours. Conclusion the obstetric profile of women who experience gestational loss does not differ from the profile found in Brazil; curettage was the most used final therapy, in addition to some unfavorable outcomes, such as longer hospitalization and excessive exposure to medication.

El Misofar® como prostaglandina facilitadora: una nueva opción en obstetricia / Misofar® as facilitator prostaglandin: a new option in obstetrics

La inducción del parto resulta un procedimiento elemental en la práctica obstétrica, que se aplica en un grupo importante de pacientes para interrumpir con éxito el embarazo debido a riesgos materno y perinatal. En este artículo se expone brevemente un nuevo método que permite abordar con efectividad la respuesta a la oxitocina, después del uso del Misofar® en función facilitadora para inducir el parto, acortando la latencia en la rotura prematura de membranas y condicionando las estructuras cervicales en gestantes con preeclampsia para obtener una mejor respuesta. Esta nueva herramienta se pone a disposición de la comunidad médica, en beneficio materno y perinatal.

Labor induction is an elementary procedure in obstetrics that is applied in an important group of patients to successfully interrupt pregnancy due to maternal and perinatal risks. In this work, a new method that allows to approach with effectiveness the oxytocin response is briefly exposed, after the use of Misofar® in facilitator function to induce labor, shortening the latency in early break of membranes and conditioning the cervical structures in pregnant women with pre-eclampsia to obtain a better response. This new tool is at medical community disposal for the maternal and perinatal benefit.

Vaginal misoprostol versus bilateral uterine artery ligation in decreasing blood loss in trans-abdominal myomectomy: a randomized controlled trial

Background: Uterine leimyomas are tumors of the smooth muscles and the connective tissues of the uterus. They are considered to be the most common benign pelvic tumor affecting about 20% of women above the age of 35. The diverse symptomatology of fibroids can be attributed to size, number and location of the tumors. The common symptoms include menorrhagia, infertility, abdominal mass and pressure effects

Aim of the Work: The aim of this study is to compare between the effect of medical [preoperative vaginal misoprostol] and non-medical [bilateral uterine artery ligation] regarding their efficacy to decrease blood loss in trans- abdominal myomectomy

Patients and Methods: Prospective randomized controlled interventional clinical trial. The study was conducted in Ain Shams University Maternity Hospital, Cairo, Egypt in the period between August 2015 till December 2016. It was approved by the Ethical Research Committee, Obstetrics and Gynecology Department, Ain Shams University, Cairo, Egypt. It included 60 women recruited from those attending the outpatient gynecology clinic, seeking treatment for symptomatic uterine myomas

Results: The current study revealed that there was no statistically significant difference between both groups regarding operative time, blood loss and postoperative hospital stay. Conclusion: A single pre-operative dose of 400 micrograms of vaginal misoprostol is as effective as uterine artery ligation in decreasing blood loss in transabdominal myomectomy. Misoprostol is a simple, cheap, fast, available and applicable tool that can be administered even an hour preoperatively

Recommendations: Preoperative vaginal misoprostol is an effective practical tool in decreasing blood loss in transabdominal myomectomy. Investigation of misoprostol use in larger population groups and with different dosages and administration routes, together with comparison of other methods used to reduce bleeding during myomectomy, is recommended

Mid trimester termination; PGF2 alpha versus misoprostol

The objective of study was to compare the efficacy of extra amniotic prostaglandin F2 alpha and vaginal misoprostol for termination of 2nd trimester pregnancy. It was quasi experimental study. The study was conducted at Gynae Unit II, DHQ Hospital affiliated with Punjab Medical College, Faisalabad for a period of one year from July 2012 to June 2013. This study included 100 patients who presented with congenitally anomalous foetus or IUD during 2nd trimester for termination of pregnancy. Outcome was evaluated by percentage of successful cases for TOP and induction to delivery interval. As regards the efficacy of misoprostol, success rate for termination of pregnancy was 86% and mean induction to delivery interval was 13.16+/-1.987 hours. Regarding PGF2 alpha success rate for TOP was 88% and mean induction to delivery interval was 16.07+/-3.202 hours. Misoprostol is comparable in its efficacy to PGF2 alpha for mid trimester termination and can be used as a cheaper alternative

Comparative Study of Misoprostol Versus Dinoprostone for Induction of Labour.

Induction of labour means initiation of uterine contractions (after the period of viability) by any method (medical, surgical or combined) for the purpose of vaginal delivery. It is helpful when the risks of continuation of pregnancy either to the mother or the fetus is more. Some unfavourable conditions like IUGR, PROM, Post –term pregnancy, IUD, Chorioamnionitis, Maternal medical problems like PIH, Diabetes Mellitus, Renal diseases, COPD, Cardiac diseases may call for induction of labour. Various Pharmacological methods have been introduced for both pre-induction cervical ripening and induction of labour are as follows- 1) Prostaglandins 2) Oxytocin 3) Steroid receptor antagonist-Mifepristone 4) Relaxin This study was conducted on nulliparous females in the age group of 20-30yrs, with gestational age more than 34 wks in the Dept. Of Obstetrics and Gynaecology, Index Medical College Hospital and Research Centre Khudel, Indore over a period of 1 year with a sample size of 100 and they were randomized into Group A-receiving 50mcg of misoprost tablet vaginally and Group B -receiving endocervical cerviprime gel. Hence the purpose of this study is to emphasize that misoprostol is a better alternative than dinoprostone for induction of labour at rural hospital setup by comparing their- 1) Success Rate 2) Induction –delivery interval 3) Number of doses required, their cost effectiveness 4) Maternal complications 5) Fetal complications Among these prostaglandins especially prostaglandin E1,because of their short induction delivery interval, easy availability, low price, easy storage at room temperature, low maternal and fetal complication appear to be especially useful.

Efectividad del tratamiento médico con misoprostol en pacientes con aborto incompleto que acudieron al Hospital Nacional Dos de Mayo: enero-diciembre 2012 / Effectiveness of medical treatment with misoprostol in patients with incomplete abortion attended at the National Hospital Dos de Mayo: january-december 2012

El presente trabajo de investigación surge a raíz de la resistencia, temor y la falta de compromiso del personal médico del HNDM (Hospital Nacional Dos de Mayo) para incorporar el Misoprostol como primera alternativa en el tratamiento del aborto incompleto precoz, esto quizás por el miedo a las complicaciones y por ende a los problemas médico legales a pesar de que existen varias revisiones sistemáticas quienes demuestran fehacientemente la efectividad del Misoprostol en el tratamiento del aborto incompleto precoz. Este trabajo de investigación es mediante un estudio Descriptivo, Transversal y retrospectivo el cual nos permitirá demostrar una vez más la efectividad y beneficios del Misoprostol en pacientes que acudieron al HNDM y que fueron diagnosticados de aborto incompleto y recibieron tratamiento médico con Misoprostol en relación al Tx quirúrgico, esto permitirá motivar al personal de salud del HNDM a incorporar al Misoprostol como tratamiento de primera línea en el aborto incompleto precoz. El número total de abortos en general en el Hospital Nacional Dos de Mayo en el periodo de Enero a Diciembre del 2012 fue 496 de los cuales 322 (65 por ciento) fueron aborto incompleto que cumplían los criterios para el TX médico, y solo 111 (34 por ciento) recibieron tratamiento médico con misoprostol 600 mcg vía oral en dosis única y 153 (48 por ciento) termino en AMEU y 58 (18 por ciento) en EBA más LU. El servicio de Gineco Obstetricia del HNDM cuenta con 28 Gíneco Obstetras de los cuales solo 12 (43 por ciento) realiza tratamiento médico con misoprostol y 16 (57 por ciento) tratamiento quirúrgico (AMEU-LU) a pacientes con aborto incompleto que cumplen los criterios para TX médico, siendo las principales causas: resistencia al cambio 56 por ciento, temor a las complicaciones 31 por ciento y falta de capacitación 13 por ciento. De un total de 111 HCL con abortos incompletos que reciben tratamiento médico con misoprostol el 78 por ciento son menores de 30 años y el...

The present research stems from the resistance, fear and lack of commitment HNDM medical staff to incorporate Misoprostol as first aIternate in the earIy treatment of incompIete abortion, that perhaps the fear of compIications and hence medico-legal probIems even though there are several systematic reviews who clearly demonstrate the effectiveness of MisoprostoI in the treatment of earIy incomplete abortion. This research is a descriptive, transversal and retrospective which will allow us to further demonstrate the effectiveness of Misoprostol in patients attending the HNDM and who were diagnosed with incomplete abortion with Misoprostol received medical treatment, this will allow us to motivate the HNDM health staff to incorporate the Misoprostol as first line treatment of incomplete abortion in earIy. The total number of abortions in general in the National Hospital Dos de Mayo in the period from January to December 2012 was 496 of which 322 (65 per cent) were incomplete abortion that met the criteria for the TX doctor, and only 111 (34 per cent) received medical treatment with Misoprostol 600 mcg orally in a single dose and 153 (48 per cent) ended in MV A and 58 (18 per cent) in aduIt education more LV The Department of Obstetrics and Gynecology of the HNDM account with 28 Ob/gyns of which only 12 (43 per cent) performs medical treatment with Misoprostol and 16 (57 per cent) TX in surgical patients with incomplete abortion that meet the criteria for TX doctor, being the main causes: resistance to change 56 per cent, fear of complications 31 per cent and lack of training 13 per cent. A total of 111 HCL with incomplete abortions that receive medical treatment with Misoprostol 78 per cent are under 30 years of age and 39 per cent and 33 per cent come from the District of Lima and Victory respectively, 52 per cent have full high school education and 31 per cent complete primary school, on the other hand, the 41 per cent are housewife and 53 per cent merchant...

Evaluation of Misoprostol in the Medical Management of Abortion.

The present study was carried out to compare the safety and efficacy of Misoprostol with Surgical Evacuation in the management of abortion. 100 women as specified by the inclusion and exclusion criteria were recruited for this prospective observational study. 50 subjects (Group A) were managed medically by Misoprostol and 50 subjects (Group B) underwent Surgical Evacuation. Clinical outcome, time taken for expulsion, number of doses required, mean duration of hospital stay, mean analgesic requirement, mean blood loss and side effects were compared between the two groups. It was concluded that vaginal administration of Misoprostol is a safe, effective and cheap alternative to surgical evacuation. No serious adverse effects were observed with Misoprostol.

Dos modalidades terapéuticas en el alumbramiento activo / Two therapeutic modalities in the active childbirth

Se utilizó un nuevo plan terapéutico para el alumbramiento activo, basado en el empleo de misoprostol por vía sublingual, con vistas a evaluar su eficacia y seguridad. Para ello se realizó un ensayo clínico pragmático de fase III con características específicas, que incluyó a gestantes tomadas como controles y tratadas según lo normado en ese caso, así como 2 grupos experimentales (1 y 2), en cuyas integrantes se empleó el proceder activo no invasivo propuesto para el estudio. La muestra quedó conformada por 600 pacientes atendidas en el Servicio de Partos del Hospital Ginecoobstétrico Mariana Grajales Coello de Santiago de Cuba desde junio de 2009 hasta igual mes de 2010. En los 2 últimos, tanto el tiempo de alumbramiento promedio como el volumen de sangrado calculado fueron menores que en el primero, de donde se concluyó que el misoprostol a las dosis y vía propuestas resultó ser más eficaz y seguro que la oxitocina

A new therapeutic plan was used for the active childbirth, based on sublingual misoprostol use, aimed at evaluating its effectiveness and safety. For this, a phase III pragmatic clinical trial was carried out with specific characteristics that included pregnant women taken as controls and treated according to the standards in that case, as well as 2 experimental groups (1 and 2) in whom the active and non invasive procedure proposed for the study was used. The sample was formed by 600 pregnant women assisted at the Childbirth Service of Mariana Grajales Coello Gynecological and Obstetrical Hospital in Santiago de Cuba from June, 2009 to the same month of 2010. In the 2 last groups, both the time of average childbirth and the volume of calculated bleeding were smaller than in the first one, and it was concluded that misoprostol at the doses and administration route proposed turned out to be more effective and safe than oxytocin

Misoprostol en la inducción del parto: experiencias en el Queen Elizabeth II Hospital de Maseru, Lesotho / Misoprostol (Cytotec) for artificial delivery: experiences at Queen Elizabeth II Hospital from Maseru, Lesotho

La inducción del parto con misoprostol es un procedimiento médico reconocido por la Organización Mundial de la Salud como práctica clínica beneficiosa para la madre y el perinato y, por ello, los autores de este trabajo se propusieron sistematizar su aplicación por vía vaginal, en dosis de 50 µg (máxima de 200 µg) e intervalos de 4 horas, en gestantes seleccionadas (n= 468) con criterio de interrupción médica del embarazo, ingresadas y tratadas en el Hospital Queen Elizabeth II -- institución de referencia nacional -- de Maseru, capital de Lesotho. Se considera que las experiencias y resultados obtenidos pueden ser de apreciable utilidad para los colegas que en circunstancias y condiciones similares, brinden atención médica internacionalista, puesto que la inducción del parto con ese producto fue altamente efectiva, por cuanto disminuyó el índice de cesáreas; mostró muy buen pronóstico de vida y salud, según puntaje de Apgar al quinto minuto, morbilidad y mortalidad del peripato, así como también garantizó que la morbilidad materna se correspondiera con el patrón de la población obstétrica en general y que no se produjeran defunciones.

Artificial abortion using Misoprostol is a medical procedure recognized by the World Health Organization as a clinical practice that benefits both the mother and the neonate. That is why the authors of the present work proposed to systematize its vaginal application using doses of 50 µg (200 µg as maximum) and time periods of 4 hours in pregnant women (n= 468) who were chosen under the criterion of medical pregnancy interruption and hospitalized and treated at Queen Elizabeth II Hospital -- a national reference institution -- from Maseru, capital of Lesotho. Experiences and results obtained are considered of high usefulness for colleagues who, under similar conditions and circumstances, provide international medical care. Artificial abortion using this product was highly effective; thus, rates of abdominal delivery decreased, life and health prognosis was very good according to Apgar score at fifth minute, and morbidity and mortality of the neonate were also good. In addition, maternal morbidity matched the model of general obstetric population and no death occurred.

Sublingual misoprostol: A better choice for cervical priming before manual vacuum aspiration.

Background: Misoprostol is effective for cervical priming before manual vacuum aspiration (MVA). Aim of study was to determine whether sublingual misoprostol with a shorter interval of 2 hours before MVA would be as effective as its standard vaginal administration. Study Design: This randomized control trial included 82 women randomly assigned to receive 400 mcg of misoprostol, either sublingually or vaginally. MVA was performed 2 hours and 3 hours after in sublingual and vaginal group, respectively. Results: Cervical dilatation of 8 mm was achieved within 2 hours in sublingual group. Mean time taken for procedure (14.4 ± 5.3: sublingual group and 16.2 ± 5.7: vaginal group), and blood loss was comparable (12.2 ± 9.7 ml in sublingual group and 13.7 ± 8.5 ml in vaginal group). Conclusion: 2 hour of cervical priming with 400 mcg of sublingual misoprostol before MVA was as good as 3 hours with vaginal administration of the same dose.

Métodos farmacológicos de indução do trabalho de parto: qual o melhor? / Pharmacological methods for induction of labor: what's the best?

A indução do parto consiste em estimular artificialmente as contrações uterinas coordenadas e efetivas antes de seu início espontâneo, levando ao desencadeamento do trabalho de parto em mulheres que ultrapassaram a 22ª semana de gravidez. A antecipação do parto pode ser necessária em diversas situações obstétricas, como gestação prolongada, diabetes, ruptura prematura das membranas e pré-eclâmpsia. Estima-se que mais de 15% de todas as gestantes apresentem alguma indicação de indução do parto. Vários métodos de indução do parto são propostos, tanto naturais como artificiais e, dentre estes, os métodos farmacológicos merecem especial destaque. Realizou-se uma revisão da literatura baseada nos melhores níveis de evidências e considerando os graus de recomendação. De acordo com a literatura, a utilização de estrogênio, propranolol, relaxina, mefepristone e hialuronidade não deve ser estimulada por não existirem evidências suficientes para a sua recomendação. O seu uso, portanto, deve ser limitado a protocolos de pesquisas. Ocitocina é um método de indução efetivo que pode ser usado em pacientes com ruptura das membranas amnióticas. Prostaglandinas (PG) e misoprostol (um éster sintético da PGE1) são efetivos para a indução do parto independentemente da integridade das membranas. Prostaglandinas devem ser administradas preferencialmente por via vaginal. Habitualmente, o misoprostol é preferido devido a questões práticas, como o baixo custo e a facilidade de administração e estocagem. Doses baixas de misoprostol devem ser utilizadas e a atualmente recomendada é de 25 g a cada 4 ou 6 horas. Tanto a via oral como a via vaginal podem ser utilizadas.

Induction of labor consists of stimulation of effective and coordinated uterine contractions before their spontaneous onset for the purpose of bring on labor in women who have surpassed the 22nd week of pregnancy. In several obstetrical situations, such as prolonged pregnancy, diabetes, premature rupture of membranes and preeclampsia, anticipation of labor and delivery may be necessary. It is estimated that more than 15% of all pregnant women eventually present any indication for induction of labor. Several natural and artificial methods for induction are proposed. Among them, pharmacological methods are the most relevant. A literature review was carried out based on the highest levels of evidence and on the grade of recommendations. According to the literature, the use of estrogens, relaxin, mifepristone and hyaluronidade should not be stimulated because there are not enough evidences for their recommendation, so their utilization should be limited to research protocols. Oxytocin is an effective method for induction of labor that may be used in patients with ruptured membranes. On the other hand, prostaglandins and misoprostol (a prostaglandin E1 analog) are effective for induction of labor independently on the membrane integrity. Vaginal administration should be preferred for prostaglandins. Misoprostol is habitually preferred due to practical questions, such as low cost and facility for storage and administration. Low doses of misoprostol should be used, and the currently recommended dose is 25 g every four or six hours. Both vaginal and oral routes of administration can be used.

O uso do misoprostol para indução do trabalho de parto / Use of misoprostol for induction of labor

Atualmente, estão disponíveis diversos métodos de indução do parto. Entretanto, ainda não há consenso sobre o mais efetivo e com menor frequência de efeitos adversos. O misoprostol administrado por via vaginal tem sido utilizado rotineiramente tanto para amadurecimento como para indução do parto, porém outras formas de administração vêm sendo propostas, como comprimido oral, sublingual, bucal, retal e, mais recentemente, solução oral com dose escalonada. A via de administração recomendada pelas diretrizes de sociedades de ginecologia e obstetrícia continua sendo a vaginal, porém ainda é necessário definir qual a melhor e a menor dosagem capaz de desencadear o trabalho de parto, com a menor incidência de complicações. A dose recomendada atualmente é de 25 ug a cada quatro ou seis horas. A administração oral do misoprostol apresenta efetividade semelhante à vaginal, porém novos estudos ainda são necessários para determinar o melhor esquema terapêutico. As vias de administração bucal, sublingual e retal devem ser reservadas a protocolos de pesquisas, devendo ser estimulada a realização de novos estudos para determinar se existem vantagens em relação à via vaginal, além de definir a menor dose eficaz e o perfil de segurança.

Currently, several methods for induction of labor are available, but it remains uncertain which is more effective and safe with less frequency of adverse effects. Vaginal misoprostol has been utilized routinely for both preparation of cervix and induction of labor. However, other routes of administration have been proposed, like oral, sublingual, buccal, rectal and, recently, a titrated oral solution. Guidelines continue to recommend vaginal administration, but it is necessary to define the best and lowest dose capable of starting labor with fewer complications. The current recommended dose of vaginal misoprostol is 25 ug each four or six hours. Oral misoprostol has effectiveness similar to vaginal misoprostol, but new trials are still necessary to determine the ideal therapeutic schema. Buccal, sublingual and rectal routes should be restricted to research protocols. Randomized controlled trials should be conducted to determine whether there are advantages of these alternative routes in relation to vaginal administrations and to define their safety profile, as well as the ideal dose for labor induction

Misoprostol en la interrupción temprana del embarazo en pacientes adolescentes / Misoprostol in early termination of pregnancy in adolescents

OBJETIVO: evaluar la eficacia y seguridad del misoprostol vaginal como abortivo y la indicación de este proceder en la adolescencia. MÉTODOS: nuestra investigación se trata de un ensayo clínico aleatorio, abierto, monocéntrico, con un grupo de tratamiento para extender el uso de un método abortivo farmacológico en pacientes que solicitan interrupción de la gestación hasta las 12 sem de embarazo y hasta los 20 años de edad. Se incluyeron todas las pacientes adolescentes que acudieron a la consulta de interrupción de embarazo del hospital Ramón González Coro y que cumplieron con los criterios de inclusión, en un cohorte de 100 casos. RESULTADOS: los resultados encontrados muestran que el 89 % de las adolescentes tenían más de 16 años, las primeras relaciones sexuales (76 %) fueron antes de los 16 años y las infecciones de tramisión sexual (ITS) aparecen en el 51 %. Con respecto al método el 71 % expulsó antes de las 16 h de impuesto (primera y segunda dosis) con una tasa de fallo del 8 %.Todas fueron estudiadas con US a las 72 h. El 85 % considera satisfactorio el método y 96 salieron con algún método anticonceptivo. CONCLUSIÓN: el uso del misoprostol por vía vaginal en la adolescencia resultó ser un método útil y confiable como alternativa para la interrupción del embarazo en el primer trimestre

OBJECTIVE: To assess the effectiveness and safety of vaginal Misoprostol as abortive method and indication of this procedure during adolescence. METHODS: Present research is a monocenter, open, randomized clinical trial with a group of treatment to extend the use of a pharmacologic abortive method in patients requesting pregnancy termination until the12 weeks and also until 20 years old. All the adolescent patients seen in pregnancy termination consultation of ½Ram¾n Gonzßlez Coro» Gynecology and Obstetrics Hospital fulfilling with inclusion criteria in a group of 100 cases are included. RESULTS: Results achieved show that the 89 percent of adolescents aged over 16, their first sexual intercourses were before 16 years and ITS (appear in the 51 percent. Regarding the method, the 71 percent had a expulsion rate before the 16 h of application (first and second dose) with an 8 percent failure rate. All were studied using US at 72 h. The 85 percent considers that the method was satisfactory and in the 96 percent some contraceptive method was used. CONCLUSION: The use of vaginal Misoprostol during the adolescence was a useful and reliable method as alternative for pregnancy termination at first trimester

O uso do misoprostol para indução do parto de feto vivo / The misoprostol use in labor initiation with live fetus

A partir da década de 1980, o misoprostol inicialmente usado em Gastroenterologia, logo foi adotado para uso obstétrico, tanto legal quanto ilegal. De droga vista com desconfiança inicialmente, tornou-se método de escolha nos melhores centros obstétricos. Este estudo teve como objetivo uma atualização do uso do misoprostol para a indução do parto de feto vivo nas várias vias e formas de aplicação. Foi feita uma avaliação das várias vias de aplicação e as dosagens recomendadas pelos autores referendados, com análise crítica da sua efetividade. Conclui-se pela efetividade e segurança do método, ser no momento o método recomendado pelo Ministério da Saúde e pela Federação Brasileira das Associações de Ginecologia e Obstetrícia.

From the 1980s, misoprostol used initially in Gastroenterology, was soon adopted for obstetrics use, legal or illegal. It was considered an unbelieved drug at the begining, but now is the first choice in the best obstetric centers. The purpose of this study was to update the misoprostol use in labor induction with live fetus, at several ways and administration forms. An evaluation of the several administration ways and of the recommended doses by referenced authors was done, with critical analysis of its efficacy. By the method's effectiveness and security it was concluded that the misoprostol is recommended to labor induction for the Brazylian Health Minister, and the Brazilian Federation of Gynecology and Obstetrics.